1
|
Hirunsai M, Srikuea R. Differential effects of cholecalciferol and calcitriol on muscle proteolysis and oxidative stress in angiotensin II-induced C2C12 myotube atrophy. Physiol Rep 2024; 12:e16011. [PMID: 38627219 PMCID: PMC11021198 DOI: 10.14814/phy2.16011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Revised: 03/13/2024] [Accepted: 03/29/2024] [Indexed: 04/19/2024] Open
Abstract
Renin-angiotensin system activation contributes to skeletal muscle atrophy in aging individuals with chronic diseases. We aimed to explore the effects of cholecalciferol (VD3) and calcitriol (1,25VD3) on signaling of muscle proteolysis and oxidative stress in myotubes challenged with angiotensin II (AII). The mouse C2C12 myotubes were assigned to vehicle, AII, AII + VD3, AII + 1,25VD3, and AII + losartan groups. The expression levels of muscle-specific E3 ubiquitin ligase proteins, autophagy-related proteins, and oxidative stress markers were investigated. We demonstrated the diverse effects of VD3 and 1,25VD3 on AII-induced myotube atrophy. The myotube diameter was preserved by treatment with 100 nM VD3 and losartan, while 1 and 10 nM 1,25VD3 increased levels of FoxO3a, MuRF1, and atrogin-1 protein expression in myotubes exposed to AII. Treatment with AII + 10 nM 1,25VD3 resulted in the upregulation of LC3B-II, LC3B-II/LC3B-I, and mature cathepsin L, which are autophagic marker proteins. The p62/SQSTM1 protein was downregulated and vitamin D receptor was upregulated after treatment with AII + 10 nM 1,25VD3. A cellular redox imbalance was observed as AII + 10 nM 1,25VD3-induced reactive oxygen species and NADPH oxidase-2 overproduction, and these changes were associated with an inadequate response of antioxidant superoxide dismutase-1 and catalase proteins. Collectively, these findings provide a translational perspective on the role of vitamin D3 in alleviating muscle atrophy related to high levels of AII.
Collapse
Affiliation(s)
- Muthita Hirunsai
- Department of Biopharmacy, Faculty of PharmacySrinakharinwirot UniversityNakhon NayokThailand
| | - Ratchakrit Srikuea
- Department of Physiology, Faculty of ScienceMahidol UniversityBangkokThailand
| |
Collapse
|
2
|
Elsaeed MY, Mehanna OM, Abd-Allah EEE, Hassan MG, Ahmed WMS, Moustafa AEGA, Eldesoky GE, Hammad AM, Elgazzar UB, Elnady MR, Abd-Allah FM, Shipl WM, Younes AM, Magar MR, Amer AE, Abbas MAM, Elhamaky KSA, Hassan MHM. Combination Therapy with Enalapril and Paricalcitol Ameliorates Streptozotocin Diabetes-Induced Testicular Dysfunction in Rats via Mitigation of Inflammation, Apoptosis, and Oxidative Stress. PATHOPHYSIOLOGY 2023; 30:567-585. [PMID: 38133142 PMCID: PMC10747062 DOI: 10.3390/pathophysiology30040041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2023] [Revised: 11/12/2023] [Accepted: 11/21/2023] [Indexed: 12/23/2023] Open
Abstract
BACKGROUND As the impacts of diabetes-induced reproductive damage are now evident in young people, we are now in urgent need to devise new ways to protect and enhance the reproductive health of diabetic people. The present study aimed to evaluate the protective effects of enalapril (an ACE inhibitor) and paricalcitol (a vitamin D analog), individually or in combination, on streptozotocin (STZ)-diabetes-induced testicular dysfunction in rats and to identify the possible mechanisms for this protection. MATERIAL AND METHODS This study was carried out on 50 male Sprague-Dawley rats; 10 normal rats were allocated as a non-diabetic control group. A total of 40 rats developed diabetes after receiving a single dose of STZ; then, the diabetic rats were divided into four groups of equivalent numbers assigned as diabetic control, enalapril-treated, paricalcitol-treated, and combined enalapril-and-paricalcitol-treated groups. The effects of mono and combined therapy with paricalcitol and enalapril on testicular functions, sperm activity, glycemic state oxidative stress, and inflammatory parameters, as well as histopathological examinations, were assessed in comparison with the normal and diabetic control rats. RESULTS As a result of diabetes induction, epididymal sperm count, sperm motility, serum levels of testosterone, follicle-stimulating hormone (FSH) as well as luteinizing hormone (LH), and the antioxidant enzyme activities, were significantly decreased, while abnormal sperm (%), insulin resistance, nitric oxide (NO), malondialdehyde (MDA), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were significantly increased, along with severe distortion of the testicular structure. Interestingly, treatment with paricalcitol and enalapril, either alone or in combination, significantly improved the sperm parameters, increased antioxidant enzyme activities in addition to serum levels of testosterone, FSH, and LH, reduced insulin resistance, IL-6, and TNF-α levels, and finally ameliorated the diabetes-induced testicular oxidative stress and histopathological damage, with somewhat superior effect for paricalcitol monotherapy and combined therapy with both drugs compared to monotherapy with enalapril alone. CONCLUSIONS Monotherapy with paricalcitol and its combination therapy with enalapril has a somewhat superior effect in improving diabetes-induced testicular dysfunction (most probably as a result of their hypoglycemic, antioxidant, anti-inflammatory, and anti-apoptotic properties) compared with monotherapy with enalapril alone in male rats, recommending a synergistic impact of both drugs.
Collapse
Affiliation(s)
- Magdy Y. Elsaeed
- Department of Physiology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (O.M.M.); (M.G.H.); (W.M.S.A.); (M.R.E.); (M.A.M.A.); (K.S.A.E.)
- Department of Physiology, Faculty of Medicine, HORUS University, Damietta 34517, Egypt
| | - Osama Mahmoud Mehanna
- Department of Physiology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (O.M.M.); (M.G.H.); (W.M.S.A.); (M.R.E.); (M.A.M.A.); (K.S.A.E.)
- Department of Physiology, Faculty of Medicine, HORUS University, Damietta 34517, Egypt
| | - Ezz-Eldin E. Abd-Allah
- Department of Histology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (E.-E.E.A.-A.); (A.E.G.A.M.); (F.M.A.-A.)
| | - Mohamed Gaber Hassan
- Department of Physiology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (O.M.M.); (M.G.H.); (W.M.S.A.); (M.R.E.); (M.A.M.A.); (K.S.A.E.)
- Department of Physiology, Faculty of Medicine, HORUS University, Damietta 34517, Egypt
| | - Walid Mostafa Said Ahmed
- Department of Physiology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (O.M.M.); (M.G.H.); (W.M.S.A.); (M.R.E.); (M.A.M.A.); (K.S.A.E.)
| | - Abd El Ghany A. Moustafa
- Department of Histology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (E.-E.E.A.-A.); (A.E.G.A.M.); (F.M.A.-A.)
| | - Gaber E. Eldesoky
- Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia;
| | - Amal M. Hammad
- Department of Biochemistry, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (A.M.H.); (U.B.E.)
| | - Usama Bahgat Elgazzar
- Department of Biochemistry, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (A.M.H.); (U.B.E.)
| | - Mohamed R. Elnady
- Department of Physiology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (O.M.M.); (M.G.H.); (W.M.S.A.); (M.R.E.); (M.A.M.A.); (K.S.A.E.)
- Department of Physiology, Faculty of Medicine, HORUS University, Damietta 34517, Egypt
| | - Fatma M. Abd-Allah
- Department of Histology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (E.-E.E.A.-A.); (A.E.G.A.M.); (F.M.A.-A.)
| | - Walaa M. Shipl
- Department of Biochemistry and Molecular Biology, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11765, Egypt;
| | - Amr Mohamed Younes
- Department of Basic Dental Sciences, Faculty of Dentistry, Applied Science Private University, Al-Arab Street, Amman 11196, Jordan;
- Department of Anatomy and Embryology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (A.E.A.); (M.H.M.H.)
| | - Mostafa Rizk Magar
- Department of Restorative Dentistry and Basic Medical Sciences, Faculty of Dentistry, University of Petra, Amman 11196, Jordan;
- Department of Anatomy and Embryology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (A.E.A.); (M.H.M.H.)
| | - Ahmed E. Amer
- Department of Anatomy and Embryology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (A.E.A.); (M.H.M.H.)
| | - Mohamed Ali Mahmoud Abbas
- Department of Physiology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (O.M.M.); (M.G.H.); (W.M.S.A.); (M.R.E.); (M.A.M.A.); (K.S.A.E.)
- Department of Basic Dental Sciences, Faculty of Dentistry, Applied Science Private University, Al-Arab Street, Amman 11196, Jordan;
| | - Khaled Saleh Ali Elhamaky
- Department of Physiology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (O.M.M.); (M.G.H.); (W.M.S.A.); (M.R.E.); (M.A.M.A.); (K.S.A.E.)
| | - Mohammed Hussien Mohammed Hassan
- Department of Anatomy and Embryology, Damietta Faculty of Medicine, Al-Azhar University, Damietta 34517, Egypt; (A.E.A.); (M.H.M.H.)
| |
Collapse
|
4
|
Ahmed OM, Ali TM, Abdel Gaid MA, Elberry AA. Effects of enalapril and paricalcitol treatment on diabetic nephropathy and renal expressions of TNF-α, p53, caspase-3 and Bcl-2 in STZ-induced diabetic rats. PLoS One 2019; 14:e0214349. [PMID: 31527864 PMCID: PMC6748411 DOI: 10.1371/journal.pone.0214349] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2019] [Accepted: 08/05/2019] [Indexed: 01/04/2023] Open
Abstract
This study aimed to assess the renopreventive effect of enalapril and/or paricalcitol on streptozotocin (STZ) diabetes-induced nephropathy and to elucidate their mechanisms of action through investigation of the effects on renal oxidative stress, antioxidant defense system and expressions of TNF-α, p53, caspase-3, and Bcl-2. Diabetes mellitus was induced in fasting male Wistar rats by single intraperitoneal injection of STZ (45 mg /kg b.w.) dissolved in citrate buffer (pH 4.5). Ten days after STZ injection, the diabetic rats were treated with enalapril (25 mg/l of drinking water) and/or paricalcitol (8 μg/kg b.w. per os) dissolved in 5% DMSO daily for 4 weeks. The obtained data revealed that the treatment of diabetic Wistar rats with enalapril and/or paricalcitol led to significant decreases in the elevated serum urea, uric acid, creatinine, sodium and potassium levels; thereby reflecting the improvement of the impaired kidney function. The deteriorated kidney lipid peroxidation, GSH content and GST and catalase activities in diabetic rats were significantly ameliorated as a result of treatment with enalapril and/or paricalcitol. The elevated fasting and post-prandial serum glucose levels and the lowered serum insulin and C-peptide levels were also improved. The treatment with enalapril and paricalcitol in combination was the most potent in decreasing the elevated serum glucose levels. Moreover, the treatment of diabetic rats successfully prevented the diabetes-induced histopathological deleterious changes of kidney and islets of Langerhans of pancreas. In association, the immunohistochemically detected pro-inflammatory cytokine, TNF-α, and apoptotic mediators, p53 and caspase-3, were remarkably decreased in kidney of diabetic rats as a result of treatment while the expression of anti-apoptotic protein Bcl-2 was increased. Based on these findings, it can be concluded that enalapril and paricalcitol alone or in combination can prevent STZ diabetes-induced nephropathy through amelioration of the glycemic state and antioxidant defense system together with the suppression of oxidative stress, inflammation and apoptosis. However, the treatment of diabetic rats with enalapril and paricalcitol in combination has no further significant improvement effects on renal function and damage when compared with enalapril or paclitaxel treated diabetic groups.
Collapse
Affiliation(s)
- Osama M. Ahmed
- Experimental Obesity and Diabetes Research Lab, Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt
- * E-mail: ,
| | - Tarek M. Ali
- Department of Clinical Laboratories, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia
- Department of Physiology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
| | - Mohamed A. Abdel Gaid
- Experimental Obesity and Diabetes Research Lab, Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt
| | - Ahmed A. Elberry
- Clinical Pharmacology Department, Faculty of Medicine, Beni-Suef University, Beni-suef, Egypt
| |
Collapse
|
5
|
Inaguma D, Ito E, Koide S, Takahashi K, Hayashi H, Hasegawa M, Yuzawa Y. Combination Therapy with Renin-Angiotensin System Blockers and Vitamin D Receptor Activators for Predialysis Patients Is Associated with the Incidence of Cardiovascular Events after Dialysis Initiation: A Multicenter Nonrandomized Prospective Cohort Study. Cardiorenal Med 2017; 8:71-81. [PMID: 29344028 PMCID: PMC5757592 DOI: 10.1159/000479894] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2017] [Accepted: 07/26/2017] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Several human studies reported that the combined use of renin-angiotensin system blockers (RASBs) and vitamin D receptor activators (VDRAs) resulted in decreased urinary protein excretion. However, it is unknown whether this combination therapy influences the incidence of cardiovascular (CV) events in dialysis patients. METHODS The study was a multicenter nonrandomized prospective cohort analysis including 1,518 patients. Patients were classified into 4 groups based on medications prescribed before dialysis initiation: those who did not receive RASBs or oral VDRAs (N group), those receiving only RASBs, those receiving only VDRAs, and those receiving a combination of RASBs and VDRAs (RD group). CV events after dialysis initiation were compared using the log-rank test. Factors contributing to the incidence of CV events were examined using multivariate Cox proportional hazard regression analysis. RESULTS Significant differences were observed in the incidence of CV events and all-cause mortality between the 4 groups (p = 0.021 and p = 0.001, respectively). Cox proportional hazard analysis revealed that the incidence of CV events was significantly lower in the RD group than in the N group (hazard ratio [HR] = 0.65, 95% confidence interval [CI]: 0.50-0.86, p = 0.002). Multivariate analysis revealed that the incidence of CV events was significantly lower in the RD group than in the N group (HR = 0.66, 95% CI: 0.47-0.93, p = 0.016). CONCLUSION Combination therapy with RASBs and VDRAs in patients before dialysis initiation was associated with a reduction in CV events during maintenance dialysis.
Collapse
Affiliation(s)
- Daijo Inaguma
- Fujita Health University School of Medicine, Toyoake, Japan
| | | | | | | | | | | | | |
Collapse
|